SPY400.09-1.63 -0.41%
DIA322.78+0.55 0.17%
IXIC11,662.79-142.21 -1.20%

BRIEF-Galera Announces Topline Results From Phase 2A Aesop Trial Of Avasopasem For Chemoradiotherapy-Induced Esophagitis

reuters.com · 05/02/2022 07:14
BRIEF-Galera Announces Topline Results From Phase 2A Aesop Trial Of Avasopasem For Chemoradiotherapy-Induced Esophagitis

- Galera Therapeutics Inc GRTX:

  • GALERA ANNOUNCES TOPLINE RESULTS FROM PHASE 2A AESOP TRIAL OF AVASOPASEM FOR CHEMORADIOTHERAPY-INDUCED ESOPHAGITIS

  • GALERA THERAPEUTICS INC - INCIDENCE OF GRADE 3 ESOPHAGITIS SUBSTANTIALLY REDUCED IN PATIENTS TREATED WITH AVASOPASEM COMPARED TO LITERATURE

  • GALERA THERAPEUTICS INC - NO GRADE 4 OR 5 ESOPHAGITIS IN PATIENTS TREATED WITH AVASOPASEM

  • GALERA THERAPEUTICS INC - AVASOPASEM WAS GENERALLY WELL TOLERATED

Source text for Eikon: ID:nGNX1qQRwh

Further company coverage: GRTX


((reuters.briefs@thomsonreuters.com;))